Last reviewed · How we verify
HSV1716 Intra-pleural delivery
At a glance
| Generic name | HSV1716 Intra-pleural delivery |
|---|---|
| Also known as | Seprehvir |
| Sponsor | Virttu Biologics Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSV1716 Intra-pleural delivery CI brief — competitive landscape report
- HSV1716 Intra-pleural delivery updates RSS · CI watch RSS
- Virttu Biologics Limited portfolio CI